​ADVL1521 A Phase 2 Study of the MEK inhibitor Trametinib (IND#119346, NSC#763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Principal Investigator:
Elyssa Rubin, MD

Research Coordinator:
Kathryn Duvall
(714) 509-8646

Visit clinicaltrials.gov for more information about this trial.

  • Clinical Trial Info
  • IRB Number: 1710117
  • Protocol Number: ADVL1521
  • NCT Number: NCT03190915
  • Research Type: Leukemia
  • Phase: II
  • Status: Active - Open to Enrollment